Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Tesofensine

Triple Monoamine Reuptake Inhibitor

Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.

Human efficacy rests mainly on one 24-week Phase 2 randomised trial (TIPO-1, Astrup et al., Lancet 2008), where 0.5 mg produced roughly 9 to 11 percent placebo-subtracted weight loss, plus a Medix-run Phase 3 obesity program in Mexico that reported about 8.6 kg loss at 0.5 mg over 24 weeks but is not published as a peer-reviewed primary trial with full data. Because the pivotal data are limited, unreplicated by independent groups, and shadowed by a Lancet 2013 expression of concern about adverse-event reporting plus a documented blood-pressure and heart-rate signal, this is preliminary-to-moderate human evidence, so grade 2 rather than the prior 3.

FDA
Not FDA approved; investigational new drug in the United States, with Phase 3 obesity data generated in Mexico rather than the US
WADA
Not listed on the WADA Prohibited List by name as of 2026, though its stimulant-like triple monoamine reuptake mechanism means athletes should verify current in-competition status

Reference only. Not medical advice.

What can go wrong

Small molecule, not a peptide; dose-dependent increases in blood pressure and heart rate raise a cardiovascular safety signal, and mood or psychiatric effects and insomnia are reported, with a Lancet 2013 expression of concern over adverse-event reporting in the pivotal trial.

Not a peptide but a synthetic small-molecule triple monoamine reuptake inhibitor, frequently discussed alongside weight-loss peptides. It showed strong Phase 2 weight loss (TIPO-1) and completed a Phase 3 obesity program in Mexico, but it is not FDA or EMA approved and carries cardiovascular and psychiatric safety concerns.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • Obesity (Phase 3 in some markets)
  • Appetite suppression

How it is supposed to work

Tesofensine raises three brain chemicals at once, dopamine, norepinephrine and serotonin, by blocking the transporters that normally clear them away. Those three neurotransmitters together govern appetite and food-seeking, so the main effect is a strong reduction in appetite and food intake, with a small increase in energy expenditure on top. It is a brain-acting mechanism, fundamentally different from the gut-hormone approach of the GLP-1 drugs, and it is taken as a once-daily tablet with no titration needed.

Tesofensine (code NS2330) is a small-molecule triple monoamine reuptake inhibitor, and it is worth noting plainly that it is not a peptide, despite appearing in peptide and weight-loss conversations. It was developed by NeuroSearch and is now advanced by Saniona. Its small-molecule, orally active nature is part of its appeal, offering pill-based weight loss in a field dominated by injectable peptides.

Type
Triple monoamine reuptake inhibitor
Not a peptide
Correct
Effect
~10% weight loss
Route
Oral tablet
Approved
Mexico (not FDA)
Catch
Cardiovascular signal

Strong Weight Loss, A Heart-Rate Catch

Tesofensine’s efficacy is genuinely strong, but it comes with a cardiovascular catch. The strength is real: it was discovered by accident, causing marked weight loss as a side effect in Alzheimer’s and Parkinson’s trials, and in obesity it delivered around 10% weight loss in Phase 2, in GLP-1 territory, since confirmed in Phase 3. The honest catch is cardiovascular: by raising norepinephrine and dopamine it is sympathomimetic, speeding the heart and modestly raising blood pressure, the same class of signal that got the earlier monoamine weight-loss drug sibutramine withdrawn worldwide. That signal is the central reason US and European development stalled. It is approved or advancing only in Mexico, partly through a combination that adds a beta-blocker to blunt the heart-rate rise, and it also carries neuropsychiatric and abuse-potential concerns from its dopamine activity. Strong weight loss, with a heart-rate catch that has kept it out of the major markets.

Safety in detail

Reported adverse effects include rises in blood pressure and heart rate, dry mouth, insomnia, nausea, and mood changes, and the drug-withdrawal rate in the Phase 2 trial was higher on tesofensine than placebo. The cardiovascular signal is significant enough that the Tesomet combination pairs tesofensine with the beta-blocker metoprolol to blunt it. Tesofensine is investigational and not FDA approved, so any use outside a regulated trial is off-label and unmonitored.

  • The central concern is cardiovascular: it raises heart rate and modestly raises blood pressure, the kind of signal that got the earlier monoamine weight-loss drug sibutramine withdrawn.
  • Its dopamine and norepinephrine activity carries neuropsychiatric risk, making it inadvisable in active psychiatric disorders.
  • Dopamine-reuptake inhibition raises an abuse-potential concern, a caution in those with substance-use history.
  • Combined with certain antidepressants or MAO inhibitors, the triple reuptake action risks serotonin syndrome.
  • The Mexican combination product adds a beta-blocker to manage the heart-rate rise, which addresses but does not remove the signal.
  • It is not FDA-approved, and gray-market product carries the usual quality risks.

Children and teenagers

Tesofensine is a centrally acting, stimulant-class weight-loss drug with cardiovascular, psychiatric and abuse-potential concerns, and has no place in anyone under 18. Pediatric weight management belongs with qualified specialists, not a monoamine reuptake inhibitor sourced gray-market. There is no appropriate pediatric use.

What people get wrong

Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

Tesofensine’s legitimate commercial path runs through Saniona, its developer, and Medix, the partner holding rights in Mexico and Argentina that has driven its approval there. Outside those markets, where it is not approved, gray-market vendors and online pharmacies sell it for weight loss on the strength of its efficacy data. The tension is between genuinely strong clinical results and a narrow approval footprint, with the gray market filling the gap that the cardiovascular signal left in major markets.

How we got here

Tesofensine was synthesized at the Danish company NeuroSearch under the code NS2330 and was first investigated for Alzheimer's disease and Parkinson's disease, where trials showed weight loss as a side effect but insufficient neurological benefit, so those programs were stopped. NeuroSearch redirected it to obesity, ran the Phase 2 TIPO trials, then in 2014 transferred NS2330 and NS2359 to Saniona. Saniona and its regional partner Medix carried it through a Phase 3 obesity program in Mexico and pursued regulatory approval there, and Saniona also developed the tesofensine-plus-metoprolol combination Tesomet for hypothalamic obesity and Prader-Willi syndrome. It has never been approved by the FDA or EMA.

Tesofensine was developed by NeuroSearch for Alzheimer’s and Parkinson’s disease, where it unexpectedly caused marked weight loss. Repurposed for obesity, it produced roughly 10% weight loss in the TIPO-1 Phase 2 trial, rivaling GLP-1 drugs. But a cardiovascular signal of raised heart rate and blood pressure, echoing the withdrawn drug sibutramine, stalled its Western development. Saniona took it forward, and its partner Medix ran a successful Phase 3 program in Mexico and filed for approval, both as a standalone and as the beta-blocker combination Tesomet, with Mexican regulators issuing a favorable opinion. Gray-market use spread on the back of its strong efficacy data.

  1. 2000sDeveloped for Alzheimer’s and Parkinson’s; marked weight loss observed as a side effect.
  2. 2008TIPO-1 Phase 2 shows around 10% weight loss in obesity.
  3. 2010sCardiovascular signal and the sibutramine precedent stall Western development.
  4. 2020sSaniona and Medix complete Phase 3 in Mexico and file for approval.
  5. 2023Mexican regulators issue a favorable opinion for tesofensine in obesity.

The numbers behind the grade

Type
Triple monoamine reuptake inhibitor
Peptide
No
Weight loss
~10%
Approved
Mexico (not FDA)
Route
Oral
Catch
Cardiovascular signal

The people taking it

A strong-but-stalled weight-loss drug, notable for delivering GLP-1-level efficacy in a pill, approved only in Mexico and kept out of the major markets by a cardiovascular signal.

Tesofensine’s users split between an approved Latin American patient population, mainly in Mexico, and a gray-market weight-loss audience elsewhere drawn by its GLP-1-level efficacy and the appeal of a pill rather than an injection. Many are people seeking an oral alternative to GLP-1 drugs or who did not tolerate them, often underweighting the cardiovascular caution that shaped its limited approval.

Approved or advancing for obesity in Mexico and used gray-market elsewhere for weight loss. Strong efficacy and oral convenience, offset by a cardiovascular signal and limited approval.

Set against the alternatives

Against the GLP-1 drugs, tesofensine is intriguingly competitive on weight loss, around 10% in trials, with the convenience of a once-daily pill and no titration, but the comparison turns on safety, where GLP-1 drugs carry broad approval and even cardiovascular benefit while tesofensine carries a cardiovascular risk signal and only Mexican approval. Against sibutramine, its cautionary predecessor, the resemblance is the warning: that monoamine weight-loss drug was withdrawn worldwide for cardiovascular events, which is precisely why tesofensine’s heart-rate signal has held it back. And against stimulant-class weight-loss drugs like phentermine, it shares the appetite-suppressing power and the cardiovascular trade-off. Its strength is real, pill-based efficacy; its weakness is a safety signal that safer options have made harder to justify.

What we do not know

  • Whether its cardiovascular signal is acceptable over the long term, the question that sank sibutramine.
  • Whether it will ever clear the FDA or European regulators.
  • How it compares with GLP-1 drugs head to head on both outcomes and safety.
  • How its neuropsychiatric and abuse-potential profile plays out in real-world use.

What could change

Latin American rolloutMexican and Argentine approval defines its current real-world use.Major-market hurdleWhether it can ever overcome the cardiovascular concern elsewhere.Combination approachPairing with a beta-blocker as a way to manage the heart-rate signal.GLP-1 comparisonIts standing depends heavily on how it stacks up against dominant GLP-1 drugs.

The market for this

What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.

Where approved, it is obtained by prescription. Elsewhere it is available only gray-market or through online pharmacies, which is not an approved route and skips the cardiovascular screening such a drug warrants. In most markets, approved GLP-1 drugs are the safer, evidence-based option; anyone considering tesofensine should involve a clinician and insist on tested product.

Where approved, it is a reasonably priced prescription drug. In unapproved markets, gray-market and online supply is moderately priced. Cost aside, the key question is whether the cardiovascular trade-off is acceptable, which is exactly why its approval is limited.

The approved drug comes from Medix and Saniona under regulation in their markets. Gray-market supply for unapproved markets comes from less controlled channels where quality assurance is limited.

Medix and Saniona (approved)Manufacture and commercialize tesofensine through the regulated Mexican and Argentine pathway.China and gray-marketSupply the unapproved markets, including the US, as online or research material.Combination productThe Mexican Tesomet combination pairs it with a beta-blocker to manage the cardiovascular signal.

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Tesofensine.

Nothing outstanding on this one.

Sources

The studies that matter

  • Serendipitous discovery2000s

    Tesofensine caused marked weight loss as a side effect in Alzheimer’s and Parkinson’s trials, prompting its repurposing for obesity.

  • TIPO-1 Phase 22008

    In obese patients, 0.5 mg daily produced roughly 10% or more weight loss over 24 weeks, in the same range as leading GLP-1 drugs.

  • Phase 3 in Mexico2020s

    A Phase 3 program confirmed significant weight loss at both doses, with reductions in visceral and subcutaneous fat, cholesterol, triglycerides and insulin.

  • Cardiovascular signal2000s-2020s

    Trials showed increased heart rate and modest blood-pressure elevation, the sympathomimetic signal at the heart of its safety story.

  • Safety database2020s

    More than 20 trials and roughly 1,600 patients dosed up to a year form the basis for its Mexican regulatory filings.